IMMY is committed to addressing the global challenges of delayed, inaccurate, and inaccessible fungal diagnostics by delivering innovative, high-quality solutions that ensure the right information reaches the right people at the right time. Empowering healthcare providers to make informed treatment decisions that improve outcomes for patients worldwide. Through this commitment, we reduce diagnostic gaps and enhance the speed and precision of fungal disease detection; all while keeping the patient at the centre of everything we do. A New Standard for Fungal Diagnostics IMMY has earned a global reputation for excellence, leading the way in accurate, affordable, and rapid fungal diagnostics. Their products provide reliable detection for a wide range of fungal pathogens, including Cryptococcus, Aspergillus, Histoplasma, Candida auris, Candida species, Pneumocystis jirovecii, Coccidioides, and Blastomyces, as well as mycobacteria specimen preparation reagents. We offer a comprehensive range of diagnostic platforms—including lateral flow assays (LFAs), enzyme immunoassays (EIA), and polymerase chain reaction (PCR) reagents—designed to enhance infectious disease detection and improve patient outcomes worldwide.